mAbs Therapies for COVID-19 Update: As of 7/30/2021, REGEN-COV has an added indication for emergency use as post-exposure prophylaxis against COVID-19 in adults and pediatric individuals who are at high risk for progression to severe COVID-19, including hospitalization or death. Learn more here.
Last Updated 8/3/21
Several treatments are available to treat patients who are already diagnosed with COVID-19. Also known as COVID-19 therapeutics, these treatments commonly fall under three categories: Monoclonal antibodies (mAbs), antivirals, and convalescent plasma.
Treatment before severe illness is critical in preventing hospitalization from COVID-19. Learn how antibody treatments within the first 10 days of symptoms can help prevent severe outcomes from COVID-19:
COVID-19 therapeutics are treatments for patients who test positive for COVID-19 and may prevent COVID-19 transmission among adults and pediatric individuals who have been exposed to COVID-19. There are several categories of COVID-19 therapeutics currently available to treat patients. Among them:
To keep up-to-date with the latest information on patient eligibility and treatment guidelines, visit the NIH’s guide for COVID-19 Treatment Guidelines.
Antibody products used to treat COVID-19 include:
Of the antibody types listed above, mAbs are the only therapeutic type currently recommended by the COVID-19 Treatment Panel of the National Institutes of Health to treat outpatients with mild to moderate COVID-19 who are at high risk for severe outcomes. Treatment of non-hospitalized patients with COVID-19 convalescent plasma or SARS-CoV-2 Specific immunoglobulins is not yet recommended. Learn more here.
mAbs for COVID-19 are designed to block viral attachment and entry of the virus that causes COVID-19, thus neutralizing the virus. Patients who have been exposed to or may have COVID-19 and are not yet hospitalized may be eligible for treatment.
Patients must have a prescription from a healthcare provider in order to receive treatment. Learn more about mAbs for treating COVID-19 at the links below.
As of June 25, 2021, there are two mAb therapies available through FDA Emergency Use Authorization (EUA):
In Phase 3 clinical trials, treatment of COVID-19 with mAbs was shown to reduce the relative risk of hospitalizations or death by more than 70% in newly diagnosed COVID-19 patients who were not hospitalized.
Source: Clinical Trials Arena
COVID-19 convalescent plasma is human plasma collected from individuals whose plasma contains anti-SARS-CoV-2 antibodies and meets donor eligibility requirements. Hospitalized patients with COVID-19 may improve faster if they receive plasma from those who have recovered from COVID-19 early in the course of disease, because it may have the ability to fight the virus that causes COVID-19.
There are currently no clinical data on the use of immunoglobulins in treating patients. Trials are in development but not yet enrolling participants.
Antiviral therapeutics works to inhibit the replication of viruses in our bodies by stopping messenger RNA from relaying instructions to keep producing the genetic material needed for a virus to survive. As of June 25,2021, the only FDA-approved antiviral drug for the treatment of COVID-19 is Remdesivir.
1 On April 16, 2021, the FDA revoked the emergency use authorization (EUA) for bamlanivimab monotherapy. The current EUA for combination therapy with bamlanivimab with etesevimab remains active except in areas known to have higher circulation of the P1 variant (identified in Brazil).